Meanwhile, other pharma companies are also developing checkpoint inhibitors for adjuvant RCC, including Roche ... which is testing its Imfinzi (durvalumab) alone and in combination with CTLA4 ...

ALTHOUGH UPDATED OVERALL survival (OS) findings from KEYNOTE-564 (NCT03142334) demonstrated continued benefit in patients with clear cell renal cell carcinoma (ccRCC) who received adjuvant ...

Another trial is testing the same combination in patients with RCC, but with only 3 weeks of neoadjuvant therapy. These patients then go on to a sandwich therapy with adjuvant pembrolizumab. A ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

Durvalumab (Imfinzi, AstraZeneca) with platinum-based chemotherapy as neoadjuvant treatment, and then as monotherapy after surgery, is indicated for 'the treatment of adults with resectable (tumours ≥ ...

Tian Zhang discussed risk stratification for identifying suitable candidates with high-risk renal cell carcinoma for adjuvant therapy. Dr. Zhang initiated her presentation by delving into the ...

Background: Patients with locally advanced renal cell carcinoma (RCC) may experience recurrence after surgery. In the phase 3 KEYNOTE-564 (NCT03142334) trial, adjuvant pembrolizumab demonstrated ...

We report a case of immunotherapy-induced coeliac disease due to adjuvant durvalumab post-chemoradiotherapy in a patient receiving curative treatment for lung cancer. The patient had raised ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II ... Imfinzi, in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by Imfinzi ...

Medscape Medical News, February 08, 2024 GICS 2024 Durvalumab Plus Bevacizumab ... 2024 GUCS 2024 'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer KEYNOTE-564 is the first trial ...

Merck (MSD) has released data from the Phase III KEYNOTE-564 clinical trial of KEYTRUDA, an anti-programmed death receptor-1 (PD-1) therapy, for the adjuvant treatment of renal cell carcinoma (RCC ...